Open AccessPropensity‐adjusted association of methotrexate with overall survival in rheumatoid arthritis
Author(s) -
Wasko Mary Chester M.,
Dasgupta Abhijit,
Hubert Helen,
Fries James F.,
Ward Michael M.
Publication year - 2013
Publication title -
arthritis & rheumatism
Language(s) - English
Resource type - Journals
eISSN - 1529-0131
pISSN - 0004-3591
DOI - 10.1002/art.37723
Subject(s) - medicine , hazard ratio , rheumatoid arthritis , propensity score matching , proportional hazards model , methotrexate , confidence interval , discontinuation
Objective While medications used to treat rheumatoid arthritis (RA) may affect survival in RA, few studies take into account the propensity for medication use, which may reflect selection bias in treatment allocation in survival models. We undertook this study to examine the relationship between methotrexate (MTX) use and mortality in RA, after controlling for individual propensity scores for MTX use. Methods We studied 5,626 RA patients prospectively for 25 years to determine the risk of death associated with MTX use, modeled in time‐varying Cox regression models. We used the random forest method to generate individual propensity scores for MTX use at study entry and during followup in a time‐varying manner; these scores were included in the multivariate model. We also investigated whether selective discontinuation of MTX immediately prior to death altered the risk of mortality, and we examined the association of duration of MTX use with survival. Results During followup, 666 patients (12%) died. MTX use was associated with reduced risk of death (adjusted hazard ratio 0.30 [95% confidence interval 0.09–1.03]). Selective MTX cessation immediately before death did not account for the protective association of MTX use with mortality. Only MTX use for >1 year was associated with lower risks of mortality, but associations were not stronger with longer durations of use. Conclusion MTX use was associated with a 70% reduction in mortality in RA.